{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:05:12Z","timestamp":1779379512193,"version":"3.53.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Immunology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.it.2026.03.003","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T13:24:11Z","timestamp":1775049851000},"page":"354-358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting TLR2 agonists as immunomodulators with broad antiviral activity"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5407-2750","authenticated-orcid":false,"given":"Nongthombam","family":"Boby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1949-973X","authenticated-orcid":false,"given":"Bapi","family":"Pahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.it.2026.03.003_bb0005","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nri1391","article-title":"Toll-like receptor signalling","volume":"4","author":"Akira","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.it.2026.03.003_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012343","article-title":"The lipopeptide Pam3CSK4 inhibits Rift Valley fever virus infection and protects from encephalitis","volume":"20","author":"Griesman","year":"2024","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.it.2026.03.003_bb0015","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41586-021-04232-5","article-title":"A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity","volume":"601","author":"Heitmann","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.it.2026.03.003_bb0020","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41541-025-01185-y","article-title":"Self-assembling TLR2 agonists promote mucosal immune responses without pulmonary immunopathologic injuries in mice","volume":"10","author":"Huang","year":"2025","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.it.2026.03.003_bb0025","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3390\/pharmaceutics15030912","article-title":"Protective efficacy of a mucosal influenza vaccine formulation based on the recombinant nucleoprotein co-administered with a TLR2\/6 agonist BPPcysMPEG","volume":"15","author":"Sanchez","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.it.2026.03.003_bb0030","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1016\/j.vaccine.2018.05.090","article-title":"Fibroblast-stimulating lipopeptide-1 as a potential mucosal adjuvant enhances mucosal and systemic immune responses to enterovirus 71 vaccine","volume":"36","author":"Lin","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.it.2026.03.003_bb0035","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1021\/mp300257x","article-title":"Intranasal administration of the TLR2 agonist Pam2Cys provides rapid protection against influenza in mice","volume":"9","author":"Tan","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.it.2026.03.003_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103153","article-title":"Prophylactic intranasal administration of a TLR2\/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model","volume":"63","author":"Proud","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.it.2026.03.003_bb0045","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.01044-2024","article-title":"Priming mucosal pathogen-agnostic innate immunity with an intranasal TLR2\/6 agonist in an aged population","volume":"11","author":"Mercuri","year":"2025","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.it.2026.03.003_bb0050","article-title":"Evaluation of intranasal TLR2\/6 agonist INNA-051: safety, tolerability and proof of pharmacology","volume":"10","author":"Mercuri","year":"2024","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.it.2026.03.003_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.106063","article-title":"Discovery and development of INNA-051, a TLR2\/6 agonist for the prevention of complications resulting from viral respiratory infections","volume":"234","author":"Mercuri","year":"2025","journal-title":"Antivir. Res."},{"key":"10.1016\/j.it.2026.03.003_bb0060","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.4049\/jimmunol.1101764","article-title":"MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action","volume":"188","author":"Caproni","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.it.2026.03.003_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105483","article-title":"Induction of a strong and long-lasting neutralizing immune response by dPreS1-TLR2 agonist nanovaccine against hepatitis B virus","volume":"209","author":"Lamrayah","year":"2023","journal-title":"Antivir. Res."},{"key":"10.1016\/j.it.2026.03.003_bb0070","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1038\/s41467-023-40758-0","article-title":"Phase I\/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency","volume":"14","author":"Heitmann","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2026.03.003_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010499","article-title":"TLR2 axis on peripheral blood mononuclear cells regulates inflammatory responses to non-infectious immature dengue virus particles","volume":"18","author":"Aguilar Brise\u00f1o","year":"2022","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.it.2026.03.003_bb0080","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s41590-021-00937-x","article-title":"TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines","volume":"22","author":"Zheng","year":"2021","journal-title":"Nat. Immunol."}],"container-title":["Trends in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471490626000621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471490626000621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:11:12Z","timestamp":1779376272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471490626000621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1471490626000621"],"URL":"https:\/\/doi.org\/10.1016\/j.it.2026.03.003","relation":{},"ISSN":["1471-4906"],"issn-type":[{"value":"1471-4906","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting TLR2 agonists as immunomodulators with broad antiviral activity","name":"articletitle","label":"Article Title"},{"value":"Trends in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.it.2026.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}